CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that enrollment is continuing in its ongoing global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). Specifically, the company is reporting that it has enrolled the first patient in Spain. As part of the trial, the company has opened 37 of 59 planned clinical trial sites; the sites are located in the United States, Italy, France, Spain and Switzerland. The company noted that it plans an interim analysis of the study when 30-50% of participants reach the primary endpoint; the company anticipates that happening later this year. This review will evaluate safety as well as secondary efficacy endpoints, and enrollment will not stop during the analysis. An anthracycline, Berubicin is in a class of anticancer agents that are among the most powerful chemotherapy drugs that have proven to be effective against more types of cancer than any other class of chemotherapeutic agents. “We continue to rapidly build momentum with patient enrollment across our clinical trial sites in Europe,” said CNS Pharmaceuticals CEO John Climaco in the press release. “The pace at which we are enrolling patients is encouraging and driving us toward our planned interim analysis, which we expect mid-year 2023. We sincerely appreciate the institutions, clinicians and staff that are contributing to the conduct of this trial, and are extremely grateful to the patients that choose to participate. We are laser focused on executing on clinical development plans and look forward to providing updates.”
To view the full press release, visit https://ibn.fm/6b7Gl
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.